A detailed history of Ubs Group Ag transactions in Adagene Inc. stock. As of the latest transaction made, Ubs Group Ag holds 414 shares of ADAG stock, worth $1,237. This represents 0.0% of its overall portfolio holdings.

Number of Shares
414
Previous 1 41300.0%
Holding current value
$1,237
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.96 - $4.15 $809 - $1,713
413 Added 41300.0%
414 $1,000
Q4 2023

Feb 09, 2024

BUY
$1.31 - $1.93 $1 - $1
1 New
1 $0
Q4 2021

Feb 14, 2022

SELL
$7.4 - $14.44 $9,065 - $17,689
-1,225 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$12.7 - $20.68 $10,629 - $17,309
-837 Reduced 40.59%
1,225 $18,000
Q2 2021

Aug 13, 2021

BUY
$11.8 - $17.87 $21,063 - $31,897
1,785 Added 644.4%
2,062 $28,000
Q1 2021

May 12, 2021

BUY
$17.0 - $29.99 $4,709 - $8,307
277 New
277 $5,000

Others Institutions Holding ADAG

About Adagene Inc.


  • Ticker ADAG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,423,200
  • Market Cap $130M
  • Description
  • Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...
More about ADAG
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.